BioAlliance Pharma Presents New Results on its AMEP Anti-invasive Biotherapy
BioAlliance Pharma presents new results on an innovative agent
for treating invasive cancers at the 11th Annual Meeting of the
American Society of Gene Therapy (ASGT) in Boston, May 28 to June
1, 2008
PARIS, May 30, 2008 – BioAlliance Pharma SA (Euronext Paris:
BIO; ISIN code: FR0010095596), the specialty pharmaceutical company
focused on the treatment of opportunistic infections in cancer and
HIV, has presented new in vivo results for its new entity the
AMEP™ plasmid at the 11th Annual Meeting of the American
Society of Gene Therapy (ASGT) in Boston (May 28 to June 1,
2008).
AMEP™ (a plasmid coding for a peptide which binds to surface receptors on tumor cells) is a novel anti-invasive cancer therapy. In October 2007, BioAlliance announced highly promising results for AMEP™ administered directly within tumors. The new results presented at the ASGT meeting demonstrate the efficacy of AMEP™ when administered intramuscularly. AMEP™ prompted a 53% reduction in tumor growth (proof of concept established in a melanoma model).
"This new administration route demonstrates that AMEP™ has a global, systemic effect and broadens the perspectives for treatments, in particular for metastatic melanoma ", stated Dominique Costantini, President of the Management Board and CEO at BioAlliance Pharma. “BioAlliance is gathering data to prepare the clinical trial application”.
Caroline Carmagnol
Posted: May 2008
